Odefsey (Emtricitabine, Tenofovir Alafenamide, Rilpivirine)

Emtricitabine, Tenofovir alafenamide, and Rilpivirine, the active ingredients in Odefsey, is a combination antiretroviral therapy presented as a fixed‑dose tablet for oral use. It treats HIV‑1 infection in adults and adolescents weighing at least 35 kg.

GNH USA supplies Odefsey as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Odefsey is a fixed‑dose combination antiretroviral indicated for the treatment of HIV‑1 infection in patients who have previously achieved viral suppression on a stable regimen. - HIV‑1 infection (treatment‑experienced): provides a complete, once‑daily regimen that maintains viral suppression. - HIV‑1 infection (maintenance therapy): simplifies therapy by combining three agents in one tablet, improving adherence. - HIV‑1 infection (adults and adolescents ≥35 kg): offers a single‑pill option that meets guideline‑recommended backbone and integrase‑strand‑inhibitor‑free regimens.

Adverse reactions reported with Odefsey are generally mild to moderate and reflect the pharmacology of its components.

Common Side Effects: - Nausea: mild, transient gastrointestinal upset. - Headache: occasional, resolves without intervention. - Diarrhoea: loose stools, usually self‑limiting. - Fatigue: general tiredness reported by some patients. - Insomnia: difficulty falling or staying asleep. - Rash: mild skin erythema.

Serious or Rare Side Effects: - Severe hypersensitivity reactions: including Stevens‑Johnson syndrome. - Hepatic impairment: elevated transaminases or liver injury. - Lactic acidosis: rare metabolic complication. - Severe depression or suicidal ideation: reported in a minority of patients. - Renal toxicity: rare cases of kidney function decline. - QT‑interval prolongation: uncommon cardiac effect.

When prescribing Odefsey, clinicians should consider several safety aspects. - Baseline laboratory testing: obtain hepatic, renal and viral load measurements before initiation. - Drug‑resistance testing: ensure the virus is susceptible to the components. - Co‑administration with acid‑reducing agents: may reduce rilpivirine exposure; monitor efficacy. - Pregnancy and lactation: weigh benefits against potential risks; consult guidelines. - Concomitant medications: review for interactions that may affect plasma levels. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Odefsey interacts with several drug classes; awareness of the interaction potential helps maintain therapeutic effectiveness.

Major Interactions (Avoid): - Antacids containing aluminium or magnesium: markedly reduce rilpivirine absorption. - Proton pump inhibitors (e.g., omeprazole): decrease rilpivirine exposure and may compromise viral suppression. - Rifampicin and other strong CYP3A inducers: lower plasma concentrations of rilpivirine.

Moderate Interactions (Monitor Closely): - H2‑receptor antagonists (e.g., ranitidine): may modestly reduce rilvivirine levels. - Lipid‑lowering agents (statins): increased risk of statin‑related myopathy. - Contraceptive hormones: potential reduction in hormonal efficacy. - Warfarin: possible alteration of INR values. - Antifungal azoles (e.g., ketoconazole): may increase rilpivirine concentrations.